Cure8 research brief
The paper presents a validated lab method to detect and quantify enantiomeric impurities in upadacitinib, which supports drug quality and safety for patients treated with JAK‑1 inhibitors for IBD and other conditions.
Clinicians, pharmacists, analytical chemists, formulation scientists, and researchers working on JAK inhibitors or drug quality assurance; indirectly relevant to patients on upadacitinib.
The authors developed and validated a reversed‑phase chiral HPLC method (Chiralcel OJ‑RH column) using a Box‑Behnken experimental design to optimize pH, acetonitrile content, and temperature.
The method achieved baseline separation and was validated for specificity, linearity, accuracy, precision, and robustness per ICH Q2(R2) guidelines, and was applied to a commercial tablet.
This is an abstract-level report of an analytical chemistry method; it does not provide clinical data or imply any change in drug safety or efficacy in patients.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Anadolu University - BGT-2024-2392
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Reliable laboratory methods help ensure upadacitinib tablets contain the correct amount of drug and support quality control of medicines people take for conditions including Crohn’s disease and ulcerative colitis.
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
